NeoGenomics’ Q4 Revenues Rise 23 Percent on Growing Test Volume | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer genetics testing firm NeoGenomics today reported a 23 percent increase in revenues for the fourth quarter year over year.

For the three months ended Dec. 31, 2013, Ft. Meyers, Fla.-based NeoGenomics posted revenues of $18.3 million, compared to $14.9 million a year ago. Test volume was up 28 percent during the quarter, while average revenue per test slid 4 percent, NeoGenomics said.

The company had a profit of $857,000, or $.02 per share, compared to a net loss of $113,000, or breakeven on a per-share basis, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.